Breast Cancer Videos

Videos

HR-Positive and HER2-Negative Breast Cancer Treatment Updates

06/04/2024

William J. Gradishar, MD

William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.

William J. Gradishar, MD,...

06/04/2024

Journal of Clinical Pathways

Reshma Mahtani, DO, Terry Mamounas, MD, Jane Meisel, MD

Videos

Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer

02/15/2024

In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...

In this video, a panel of...

02/15/2024

Oncology

Videos

Utilizing Clinical Pathways Tools at Cone Health

10/31/2023

Featuring John A. Ingoglia, PharmD, BCOP, CPP

Featuring John A. Ingoglia, PharmD, B...

John A. Ingoglia, PharmD, BCOP, CPP, Cone Health, provides an overview of how clinical pathways are utilized at Cone Health and shares some of the latest treatment options for breast cancer.

John A. Ingoglia, PharmD, BCOP,...

10/31/2023

Journal of Clinical Pathways

Videos

Comparison of Diversity Across Real-World Evidence, Randomized Clinical Trial, and SEER Data in Patients With Metastatic Breast Cancer

07/12/2023

Featuring Danielle Gentile, PhD

Featuring Danielle Gentile, PhD ...

Danielle Gentile, PhD, a senior scientist on Cardinal Health’s real-world evidence and insights team, discusses her research comparing diversity in real-world evidence, RCTs, and SEER data in patients with metastatic breast cancer.

Danielle Gentile, PhD, a senior...

07/12/2023

Journal of Clinical Pathways

Videos

Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment

10/16/2022

Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...

Sayeh Lavasani, MD, MS, FRCPC,...

10/16/2022

Journal of Clinical Pathways

Videos

Factors Associated With a Greater Risk of Treatment Discontinuation in High-Risk Early Breast Cancer

08/03/2022

Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...

Sara Tolaney, MD, MPH, discusses...

08/03/2022

Journal of Clinical Pathways

Videos

Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer

07/14/2022

Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...

Shlomit Amar-Farkash, PhD, MSc,...

07/14/2022

Journal of Clinical Pathways

Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network

Videos

Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer

07/06/2022

Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...

Debra Patt, MD, PhD, MBA,...

07/06/2022

Journal of Clinical Pathways

Videos

Real-World Outcomes of HR-Positive HER2-Negative Metastatic Breast Cancer Treated With ICIs

10/21/2021

Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.

Ethan Sokol, PhD, discusses...

10/21/2021

Journal of Clinical Pathways

Videos

Real-World Outcomes of Febrile Neutropenia Among Patients With Breast Cancer or Non-Hodgkin Lymphoma

05/27/2021

Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...

Weijia Wang, MSc, discusses...

05/27/2021

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Breast Cancer Videos

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products